TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
ACET

Adicet Bio Inc

Healthcare · Biotechnology

9.00$ +9.1% vs. previous close Closing price · As of: Sep 25, 2026

Ownership

Ownership Structure

Who owns Adicet Bio Inc (ACET)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 79.5% of the shares are freely tradable; institutional investors hold 64.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 64.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 1.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 79.5%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 2.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 9Mio.

Largest Shareholders

Institutions

Institutions ACET
Name Stake (%) Shares Change (%) Date
RA Capital Management, LLC 12.63 1,182,624 +24.7 03/31/2026
Orbimed Advisors LLC 10.98 1,027,944 +0.0 03/31/2026
Franklin Templeton Inc 6.69 626,571 +0.0 03/31/2026
Citadel Advisors Llc 4.62 432,738 +13.3 06/30/2026
Vanguard Capital Management, LLC 3.59 336,524 +0.0 03/31/2026
Woodline Partners LP 3.34 313,124 -49.9 03/31/2026
Adage Capital Partners Gp LLC 2.93 274,375 +0.0 06/30/2026
Renaissance Technologies Corp 2.48 232,591 -4.3 03/31/2026

Funds

Funds ACET
Name Stake (%) Shares Change (%) Date
Franklin Biotechnology Discv A(acc)USD 4.29 401,353 +0.0 07/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.60 243,228 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?